GlobeNewswire Inc | Jan 6, 2022 08:00AM EST

January 06, 2022

CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Bryan Stuart, President and Chief Executive Officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 12:00 p.m. ET.

A live audio webcast will be available through the Investor Relations section of the Fulcrum website at www.fulcrumtx.com.An archived replay will be available on Fulcrums website for 30 days.

About Fulcrum TherapeuticsFulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrumstwo lead programs in clinical development arelosmapimod, a small moleculefor the treatment offacioscapulohumeral muscular dystrophy (FSHD)and FTX-6058,a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease andother hemoglobinopathies, includingbeta-thalassemia. The companysproprietary product engine,FulcrumSeek, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression.

Please visit www.fulcrumtx.com.

Contact:

Investors: Christi Waarich Director, Investor Relations and Corporate Communicationscwaarich@fulcrumtx.com617-651-8664